Adalimumab
- PDF / 141,238 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 83 Downloads / 164 Views
1
Adalimumab Circumscribed scleroderma: case report A 17-year-old girl developed circumscribed scleroderma while receiving adalimumab for Crohn’s disease. The girl developed a round erythematous, oedematous plaque on her abdomen after her sixth injection of adalimumab 40mg every 14 days. The plaque had a warm, markedly indurated central area and a violaceous border. Skin biopsy findings were consistent with localised scleroderma. The girl was treated with locally applied corticosteroids for 20 days and mechanical massage (LPG technique). Adalimumab was replaced with azathioprine the following month after she tested positive for Mycobacterium tuberculosis; isoniazid was also started. She experienced complete clinical resolution of her circumscribed scleroderma in approximately 60 days, with no recurrence during 12 months of follow-up. Author comment: "Although no conclusion can be reached with this case, [tumour necrosis factor]-alpha may play a pivotal role in the turnover of collagen synthesis and for this reason fibrosis might occur in predisposed individuals." Mattozzi C, et al. Morphea, an unusual side effect of anti-TNF-alpha treatment. European Journal of Dermatology 20: 400-401, No. 3, May-Jun 2010. Available 803026577 from: URL: http://dx.doi.org/10.1684/ejd.2010.0946 - Italy
0114-9954/10/1311-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 24 Jul 2010 No. 1311
Data Loading...
